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Background-—Evidence shows that healthy diet, exercise, smoking interventions, and stress reduction reduce cardiovascular
disease risk. We aimed to compare the effectiveness of these lifestyle interventions for individual risk proﬁles and determine their
rank order in reducing 10-year cardiovascular disease risk.
Methods and Results-—We computed risks using the American College of Cardiology/American Heart Association Pooled
Cohort Equations for a variety of individual proﬁles. Using published literature on risk factor reductions through diverse lifestyle
interventions—group therapy for stopping smoking, Mediterranean diet, aerobic exercise (walking), and yoga—we calculated the
risk reduction through each of these interventions to determine the strategy associated with the maximum beneﬁt for each
proﬁle. Sensitivity analyses were conducted to test the robustness of the results. In the base-case analysis, yoga was associated
with the largest 10-year cardiovascular disease risk reductions (maximum absolute reduction 16.7% for the highest-risk
individuals). Walking generally ranked second (max 11.4%), followed by Mediterranean diet (max 9.2%), and group therapy for
smoking (max 1.6%). If the individual was a current smoker and successfully quit smoking (ie, achieved complete smoking
cessation), then stopping smoking yielded the largest reduction. Probabilistic and 1-way sensitivity analysis conﬁrmed the
demonstrated trend.
Conclusions-—This study reports the comparative effectiveness of several forms of lifestyle modiﬁcations and found smoking
cessation and yoga to be the most effective forms of cardiovascular disease prevention. Future research should focus on patient
adherence to personalized therapies, cost-effectiveness of these strategies, and the potential for enhanced beneﬁt
when interventions are performed simultaneously rather than as single measures. ( J Am Heart Assoc. 2016;5:e002737
doi: 10.1161/JAHA.115.002737)
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C onsensus exists that lifestyle changes such as stoppingsmoking, higher levels of physical activity, and certain
dietary patterns can lead to lower rates of cardiovascular
disease (CVD) and other chronic diseases.1–5 Current clinical
guidelines in both the United States and Europe include such
changes in their recommendations for reducing the risk of
CVD.1,6,7 For example, the 2013 American College of
Cardiology (ACC) and American Heart Association (AHA)
Guidelines to Reduce Cardiovascular Risk give a strong, Grade
A recommendation for adults who need low-density lipopro-
tein and blood pressure (BP) lowering to follow a dietary
pattern that emphasizes intake of vegetables, fruits, and
whole grains and limit intake of sweets, sugar-sweetened
beverages, and red meats.1
Clinical guidelines for providers and patients rely on
evidence that includes data analysis of individual studies,
data synthesis that pools results from many studies, and
models that use data to project future risk. An attractive
feature of models and tools that predict risk is the ability to
estimate the effectiveness of alternative strategies for
different populations and subpopulations, and for individuals
with speciﬁc characteristics. In fact, the ACC and AHA
recently published a new set of equations that can be used
to estimate 10-year and lifetime risk of a ﬁrst hard
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atherosclerotic CVD event, or ﬁrst occurrence of nonfatal
myocardial infarction or death from coronary heart disease
or fatal or nonfatal stroke.8 These equations, known as the
Pooled Cohort Equations, are based on data from diverse,
community-based cohorts that represent both black and
white men and women in the United States. Full descriptions
of the CVD risk equations and their development have been
published elsewhere.8,9
With the introduction of the ACC/AHA guidelines and the
accompanying debates on use of statin therapy, calls for
more focus on personal lifestyle modiﬁcation and behavior
change have been made.10–12 There has additionally been
growing interest in using data and analytic tools to develop
personalized recommendations that consider an individual’s
clinical risk proﬁle.13–15 Personalized recommendations uti-
lizing comparative effectiveness research have been done
previously using life expectancy gains based on US Preventive
Services Task Force guidelines,16–18 with substantial gains in
life expectancy shown with greater use of preventive
services.19
The objective of this study is to estimate the risk
reductions that can be expected from diverse lifestyle
modiﬁcations for patients with speciﬁed clinical character-
istics and establish the comparative effectiveness of these
strategies, depending on individual risk proﬁles. We calcu-
lated risk by inputting individual levels of key risk factors
including age, BP, lipid levels, hypertension treatment, and
smoking status into the Pooled Cohort Equations and then
using the best available evidence on the effects of different
interventions on each of these risk factors to establish the
comparative effectiveness of interventions for individuals
depending on their proﬁles. We considered the following
lifestyle interventions: group therapy for stopping smoking,
Mediterranean diet (a diet that emphasizes high intake of
fruits, vegetables, whole grains, fatty ﬁsh, nuts, and olive
oil),1 aerobic exercise (speciﬁcally walking), and yoga (a
popular form of exercise focusing on the mind–body
connection).
These interventions were chosen to encompass a range
of strategies that may be part of a lifestyle modiﬁcation
regimen. For stopping smoking, already well-established as a
main driver of cardiovascular risk, we chose group therapy
counseling sessions rather than nicotine replacement ther-
apy or medication to more closely align with the nonphar-
macological nature of the other strategies. A healthy diet
and aerobic exercise are regarded as mainstays in preven-
tion of CVD, with accumulating evidence on the impact of
the Mediterranean diet on cardiovascular risk.5,20,21 Yoga, a
form of physical activity that involves physical postures,
breath work, and meditation or relaxation, is becoming more
prevalent in the United States; a 2012 National Center for
Health Statistics survey showing that 9.5% of adults
(21 million) used yoga in the previous 12 months.22 Yoga
is thought to reduce response to stress and affect the
autonomic nervous system through relaxation techniques
and breath control.23,24 Three recent systematic reviews and
meta-analyses suggest that yoga may signiﬁcantly improve
risk factors for CVD such as body weight, lipid proﬁle, and
BP.25–27
Methods
This study uses the Pooled Cohort Equations published by
Goff et al to calculate 10-year CVD risk separately for white
and black individuals.8 We focused on the nondiabetic white
and black populations.
Risk factors in the equations are age, systolic BP, whether
the patient is treated for hypertension or not, total cholesterol
(TC) and high-density lipoprotein cholesterol (HDL-C), current
smoking status, and history of diabetes. Levels of risk factors
were entered in the Pooled Cohort Equations to calculate an
individual’s absolute 10-year atherosclerotic CVD risk. The
potential improvement in each risk factor that could be
achieved through the 4 lifestyle management strategies—
group therapy for smoking (only for current smokers), the
Mediterranean dietary pattern, walking, and yoga—were
Table 1. Effectiveness of Lifestyle Interventions on Reducing CVD Risk Through Changes in Risk Factors
Risk Factor
Impact of Lifestyle Changes on Risk Factor Due to Interventions
Group Therapy for Smoking Mediterranean Diet Walking Yoga
Smoking (% quitting) 9.90* (8.00, 12.30)28 — — —
Systolic blood pressure, mm Hg — 1.70 (3.35, 0.05)29 3.80 (5.90, 1.70)30 4.45 (6.99, 1.90)27
Total cholesterol, mg/dL — 7.35 (10.32, 4.39)29 3.48 (12.37, 5.80)30 17.00 (27.29, 6.71)27
HDL cholesterol, mg/dL — 0.94 (1.93, 3.82)29 2.32 (0.46, 5.41)30 2.87 (1.47, 4.26)27
CVD indicates cardiovascular disease; HDL, high-density lipoprotein.
*Probability of quitting smoking with group therapy compared to 5% probability of quitting without intervention. The relative proportion of quitting (relative risk) is 1.98 for group therapy vs
control (95% CI: 1.60–2.46).28
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obtained from published literature (Table 1). The risk factor
effect sizes were then translated into reductions in 10-year
CVD risk for each intervention.
Interventions
Intervention effect sizes were obtained from meta-analyses of
randomized controlled trials (RCTs). Published literature was
searched and meta-analyses were selected if they included
RCTs using intention-to-treat analysis, contained summary
estimates of all relevant risk factors within a single report, and
compared the treatment to a control group of no/minimal
intervention or usual care. We used an alternate set of
estimates in a sensitivity analysis.
For current smokers, group therapy for smoking cessation
consisted of about 6 to 8 scheduled meetings led by
professional facilitators for at least 6 months that included
information, advice, and encouragement for quitting.28 For
Mediterranean diet, data were taken from a meta-analysis of
RCTs in which patients followed a diet rich in fruits and
vegetables, low in red meat, and moderate in fat from nuts
and oils for at least 6 months with a follow-up of 2 years.29
Evidence on change in risk factors from walking was
obtained from a meta-analysis on pedometer use as a
means to increase physical activity.30 Speciﬁcally, partici-
pants were given a pedometer and encouraged to increase
their daily steps (either with or without a daily step goal).
This intervention resulted in an additional 2491 steps per
day, roughly equivalent to 1 mile of walking. Walking was
chosen to represent aerobic exercise as a low-impact form of
aerobic activity that is accessible and suitable for most
individuals. Mean duration of the intervention and follow-up
was 18 weeks. Data on yoga came from the most recent
meta-analysis of RCTs evaluating a variety of movement-
based yoga styles including Hatha, Vinyasa, and Ashtanga
and excluding breathing- or meditation-only styles.27 Yoga
was practiced 3 to 4 times per week on average, and the
mean duration of the yoga interventions and follow-up was
18 weeks.
Statistical Analysis
Calculations for risk factor changes as a result of lifestyle
interventions were based on an intention-to-treat approach.
The intervention effect estimates from Table 1 were added to
the initial risk factor level for an individual with speciﬁc clinical
characteristics to generate a new risk factor level. These new
levels were then entered in the Pooled Cohort Equations to
obtain a new CVD risk.
We calculated CVD risk with group therapy for smoking in
2 steps. First we calculated the CVD risk difference between a
smoker and nonsmoker, with all other risk factors unchanged
to get the pure effect of group therapy on CVD risk. Then we
multiplied this number by the probability a smoker would
successfully quit with group therapy versus no group therapy
to get the intention-to-treat estimate (see Data S1 for details
on calculations).
We calculated the absolute risk reduction of 10-year CVD
risk across the 4 different interventions for the average
patient in each risk subcategory. Base-case results were
displayed using heatmaps, using color shading to represent
gradation of risk across subgroups and strategies. Results
were stratiﬁed by sex, smoking status, and treatment for
hypertension.
We included 6 risk factor proﬁles of hypothetical patients
with varying levels of systolic BP, TC, and HDL-C with
different combinations of smoking and hypertension treat-
ment status to represent individuals with a wide range of
CVD risk, extending from 1% to nearly 30%. The 6 proﬁles
were created for both white and black patients for a total of
12 different proﬁles. For each proﬁle, we estimated the 10-
year CVD risk in the absence of a lifestyle management
intervention and with the addition of each of the 4
interventions.
Sensitivity Analysis
We conducted several analyses to explore the impact of
parameter uncertainty and the impact of alternative assump-
tions.
First, we conducted a deterministic sensitivity analysis
using the published 95% CI for the effect measure for each
intervention. We conducted a “worse case” scenario analysis
using the smallest favorable change for all risk factors and a
“best case” scenario analysis using the largest favorable
change for all risk factors.
Second, we conducted an analysis that explored the
impact on CVD risk for an individual smoker who success-
fully quits. In contrast to the primary “intention-to-treat”
analysis explained above, this secondary analysis is more
akin to a per protocol type of analysis. For example, a
provider who is considering options to recommend to a
patient will discuss the relative beneﬁts of those options
based on evidence from study results analyzed by intention-
to-treat. However, a patient might be interested in acquiring
information for the “beneﬁt” they would obtain if they
successfully stopped smoking. Therefore, we conducted an
analysis in which we assumed a patient successfully quits
and refer to this second analysis as “successful smoking
cessation.”
Third, we conducted a probabilistic sensitivity analysis to
determine how often a strategy would be considered
optimal for the 12 hypothetical patients. This analysis was
done for both the base-case analysis and the analysis with
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successful smoking cessation. In each analysis, 1000
random draws were performed in which we simultaneously
varied the parameters in Table 1—the effect size of the
interventions for each risk factor and the probability of
successfully quitting smoking with group therapy—accord-
ing to its probability density function. Intervention param-
eters were drawn from a normal distribution and the
probability of quitting smoking drawn from a beta distribu-
tion. Probability of successfully quitting was designated as
100% for the individual patient who successfully quits
smoking. The base-case intervention effect estimates were
used as means and the 95% CIs that were derived from
published literature were used to inform the spread of the
distribution.
Fourth, we used an alternative set of intervention effect
estimates from published literature for the 12 hypothetical
patient proﬁles to see if the ranking was sensitive to our
choice of meta-analysis. We have presented the table of
alternative estimates in Table S1. For smoking cessation, we
used another nonpharmaceutical intervention, physician
advice for smoking cessation, to mimic the behavior change
necessary to quit smoking.31 Another meta-analysis on the
Mediterranean dietary pattern for RCTs longer than
3 months from the Cochrane Database was selected for
this sensitivity analysis32; however, only TC was pooled and
reported and thus we varied only this parameter. To more
broadly represent exercise as an intervention, we widened
this intervention category to include more kinds of aerobic
exercise including running, jogging, and cycling. For this, we
used a recent meta-analysis of RCTs of lipid measurements
(TC and HDL)33 supplemented with a meta-analysis of the
effect of aerobic exercise on systolic BP.34 Both analyses
used similar deﬁnitions of aerobic exercise, had similar
patient populations, and both had median durations of
12 weeks (range 2–3 weeks to 2 years). An alternate meta-
analysis with similar inclusion criteria was employed for the
yoga estimates.25
Lastly, we conducted a sensitivity analysis with the general
Framingham risk score to examine if and how the relative
rankings of the interventions would change with this
commonly used risk algorithm.35 This Framingham risk score
closely matches the Pooled Cohort Equations used in the base
case, assessing all the same cardiovascular disease events
plus cardiac failure.
This study does not constitute human subjects research
and thus did not require Institutional Review Board
approval.
Results
Figures 1A through 1H and 2A through 2H display heatmaps
of risk reductions from the 4 interventions for all hypothetical
groups of patients, dichotomized by race, sex, smoking status,
and treatment for hypertension. Axes represent the covariates
—age, systolic BP, TC, and HDL—in the Pooled Cohort
Equations. In the heatmaps, the colors vary from red (smallest
risk reduction) to green (moderate risk reduction) to blue
(largest risk reduction). Differences among the strategies for
an individual patient can be observed by comparing the same
cell across the 4 different interventions.
Base Case
In general across all proﬁles displayed in the heatmaps, the
lowest risk reductions were with group therapy for smoking
(red) and the highest reductions with yoga and walking
exercise (blue). Although the results are heterogeneous
across individual patients, the largest reductions on average
were seen with yoga. The average risk reduction for all
patients was 2.6% for yoga, compared to 1.9% for walking,
1.5% for Mediterranean diet, and 0.4% for smoking cessation
counseling.
For the highest-risk individuals who may experience the
largest absolute reductions, the maximum reduction
achieved with yoga was 16.7%. Walking typically fared
second (max reduction 11.4%), followed by Mediterranean
diet (max reduction 9.2%) and then group therapy for
smoking if an individual was a current smoker (max reduction
1.6%). For some—white individuals with moderately low TC
and high levels of HDL-cholesterol and elderly black women
—Mediterranean diet outranked walking. Black subjects
generally achieved larger absolute risk reductions than white
subjects.
Table 2 shows the risk reduction achieved through the
various lifestyle modiﬁcations for the risk factor proﬁles
representing 12 hypothetical individual patients.
Sensitivity Analysis
For both the best-case and worse-case scenarios, trends were
similar to those found in the base case, with the largest risk
reductions achieved with yoga for all 12 proﬁles.
Results of our secondary sensitivity analyses assuming
successful smoking cessation are shown in column “SC” in
Table 2 with optimal strategies indicated with †. If the patient
is a smoker and successfully quits, then this lifestyle
modiﬁcation achieves the largest reductions in risk.
Probabilistic Sensitivity Analysis
Tables 3 and 4 show the results from the probabilistic
sensitivity analysis based on 1000 random draws for the base
case and successful smoking cessation analyses. The highest-
ranking strategy was yoga in over 88% of the simulations in
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Figure 1. Risk reduction by intervention for (A) white males, not treated for hypertension, nonsmoker; (B) white males, not treated for
hypertension, smoker; (C) white males, treated for hypertension, nonsmoker; (D) white males, treated for hypertension, smoker; (E) white
females, not treated for hypertension, nonsmoker; (F) white females, not treated for hypertension, smoker; (G) white females, treated for
hypertension, nonsmoker; (H) white females, treated for hypertension, smoker. Reductions range from smallest (red) to moderate (green) to
largest (blue). HDL indicates high-density lipoprotein cholesterol; SBP indicates systolic blood pressure.
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the base case, with walking being the second most frequent
optimal strategy. With successful cessation of smoking (ie,
complete smoking cessation), group therapy becomes the
dominant strategy.
Figure 1. continued.
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Alternative Estimates
Figure S1 shows the comparison of the base-case estimates
and alternative estimates for each hypothetical proﬁle. As
shown in the ﬁgure, the optimal strategy for each proﬁle does
not change, nor do the rankings among the interventions. In
fact, some absolute risk reductions are lower with the
alternate estimates compared to the base case.
Figure 1. continued.
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When the Framingham algorithm is used (see Fig-
ure S2), the relative rankings among the interventions
also remain the same. The absolute 10-year risk using the
Framingham risk equations is higher in some cases, as
Figure 1. continued.
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Figure 2. A, Risk reduction by intervention for black males, not treated for hypertension, nonsmoker; (B) black males, not treated for
hypertension, smoker; (C) black males, treated for hypertension, nonsmoker; (D) black males, treated for hypertension, smoker; (E) black
females, not treated for hypertension, nonsmoker; (F) black females, not treated for hypertension, smoker; (G) black females, treated for
hypertension, nonsmoker; (H) black females, treated for hypertension, smoker. Reductions range from smallest (red) to moderate
(green) to largest (blue). HDL indicates high-density lipoprotein cholesterol; SBP indicates systolic blood pressure.
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the Framingham risk score includes both populations in a
single score and also predicts risk of heart failure in
addition to the outcomes predicted in the Pooled Cohort
Equations.
Figure 2. continued.
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Discussion
We assessed the comparative effectiveness of 4 lifestyle
management strategies on 10-year CVD risk. In the base-
case intention-to-treat analysis, yoga resulted in the largest
risk reduction out of the 4 interventions for nonsmokers and
smokers alike. Walking as a form of aerobic exercise
generally placed after yoga, followed by Mediterranean diet.
Figure 2. continued.
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In both the deterministic and probabilistic sensitivity anal-
yses, the same trend in the base case held for our 12
hypothetical patients (yoga, walking, diet, and group therapy
for smoking).
Figure 2. continued.
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In the base-case analysis, the impact of group therapy for
stopping smoking on cardiac health was based on an
intention-to-treat calculation, in order to be consistent across
the 4 interventions; thus, only those who successfully quit
realize reduced CVD risk. With the probability of successfully
quitting being low, the beneﬁts were correspondingly minimal.
However, in a secondary analysis we demonstrated that for a
current smoker, successful smoking cessation is the most
effective of all lifestyle changes.
Our results are consistent with others who assessed the
effect of CVD prevention. A simulation model by Kahn et al that
focuses speciﬁcally on CVD interventions showed that the
greatest beneﬁts in life expectancy would be achieved through
the treatment of hypertension and elevated low-density
lipoprotein-C.36 On a population level, the large, multinational
INTERHEART case–control study found that abnormal lipids
was the most important risk factor with respect to population
attributable risk for acute myocardial infarction across all age
groups.37 Accordingly, our study shows that yoga, which
provides the largest improvements in systolic BP and lipid
levels, also provides the largest reduction in CVD risk.
In the analysis by Taksler et al, among US Preventive
Services Task Force recommendations for preventive care,
tobacco cessation, diabetes control, weight loss, and BP
reduction were consistently ranked among the top guidelines
for increases in life expectancy across patients.18 Tobacco
cessation ranked high in their study as well as the
Lifestyle Strategies for Cardiovascular Health Chu et al
Table 2. 10-Year CVD Risk (%) for Different Risk Factor Proﬁles With and Without Lifestyle Interventions With 95% Credible
Intervals
Risk Proﬁle
10-Year CVD Risk (%) With Intervention
None
Group Therapy for Smoking
MED Diet Walking YogaBC SC
1. 50-yr-old nonsmoking woman, SBP
120 mm Hg, not treated for hypertension, TC
160 mg/dL, HDL-C 50 mg/dL
White 0.9 N/A 0.8 (0.8, 0.9) 0.8 (0.7, 0.8) 0.7* (0.6, 0.8)
Black 1.4 1.2 (1.1, 1.3) 1.1 (1.0, 1.2) 1.0* (0.9, 1.1)
2. 55-yr-old nonsmoking man, SBP
140 mm Hg, treated for hypertension, TC
170 mg/dL, HDL-C 45 mg/dL
White 7.0 N/A 6.4 (6.0, 6.8) 6.2 (5.8, 6.6) 5.5* (5.1, 6.0)
Black 12.7 10.0 (9.7, 10.3) 9.7 (9.5, 9.9) 9.3* (9.0, 9.7)
3. 45-yr-old smoking man, SBP 160 mm Hg,
treated for hypertension, TC 200 mg/dL, HDL-
C 40 mg/dL
White 12.2 11.8 (11.6, 12.0) 5.0† 11.0 (10.1, 12.0) 10.6 (9.8, 11.5) 9.3* (8.4, 10.2)
Black 18.2 17.8 (17.6, 17.9) 9.4† 14.5 (14.1, 14.9) 14.1 (13.8, 14.4) 13.7* (13.2, 13.7)
4. 70-yr-old smoking woman, SBP
155 mm Hg, not treated for hypertension, TC
145 mg/dL, HDL-C 70 mg/dL
White 18.6 18.3 (18.1, 18.4) 12.1† 18.0 (18.4, 17.6) 17.6 (17.2, 18.0) 17.0* (16.3, 17.6)
Black 23.9 23.3 (23.1, 23.5) 13.3† 22.5 (21.9, 23.1) 22.5 (21.3, 23.6) 20.5* (19.1, 22.0)
5. 65-yr-old nonsmoking man, SBP
180 mm Hg, treated for hypertension, TC
200 mg/dL, HDL-C 60 mg/dL
White 23.2 N/A 22.1 (21.5, 22.8) 21.7 (21.0, 22.4) 20.5* (19.6, 21.5)
Black 27.3 22.1 (21.6, 22.6) 21.6 (21.2, 22.0) 21.0* (20.4, 21.7)
6. 50-yr-old smoking man, SBP 170 mm Hg,
treated for hypertension, TC 260 mg/dL, HDL-
C 35 mg/dL
White 28.2 27.5 (27.2, 27.8) 14.4† 26.2 (24.4, 28.4) 25.3 (24.1, 26.6) 23.2* (21.7, 24.8)
Black 28.1 27.5 (27.2, 27.7) 15.0† 22.8 (22.2, 23.4) 22.1 (21.8, 22.5) 21.6* (20.9, 22.3)
BC indicates base-case; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; MED, Mediterranean; N/A, not applicable; SBP, systolic blood pressure; SC, successful
cessation; TC, total cholesterol.
Numbers with * represent the most effective CVD risk reduction strategy in the base-case intention-to-treat analysis.
Numbers with † represent the most effective strategy assuming successful cessation of smoking.
Table 3. Percentage of Simulations That the Strategy Was
Ranked First (%) in the Base Case, by Race-Speciﬁc Risk
Proﬁle
Highest-Ranked Strategy
Risk Proﬁle
1 2 3 4 5 6
White
Group therapy for
smoking
N/A N/A 0.0 0.0 N/A 0.0
Mediterranean diet 0.3 0.3 0.3 0.0 0.1 0.6
Walking 2.5 2.2 2.5 6.6 3.6 3.7
Yoga 97.2 97.5 97.2 93.4 96.3 95.7
Black
Group therapy for
smoking
N/A N/A 0.0 0.0 N/A 0.0
Mediterranean diet 0.1 0.0 0.3 0.6 0.0 0.5
Walking 5.9 8.1 8.5 3.1 7.6 10.6
Yoga 93.9 91.9 91.2 96.3 92.4 88.9
N/A indicates not applicable.
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INTERHEART study, which demonstrated that the odds of an
acute myocardial infarction almost tripled for a current
smoker versus a nonsmoker.37 Our ﬁnding that successful
smoking cessation is the most effective of all lifestyle
changes for current smokers is consistent with these studies.
Limitations
While risk assessment was based on recently published
pooled cohort equations that allowed up-to-date, accurate,
race-speciﬁc estimation, there are several limitations of this
study. First, we focused changes in risk factors translated into
CVD risk in the nondiabetic population. Although we evaluate
diverse sets of patient characteristics, results may not
generalize to different populations. The ACC/AHA report did
not include any measures of adiposity in their algorithm,
although the lifestyle interventions studied could impact those
measures, further altering CVD risk.
Second, insufﬁcient data precluded subgroup-speciﬁc
pooled estimates of interventions on risk factors as well as
any projections of future changes in disease outcomes. Future
long-term studies could determine the effects of these
interventions on CVD outcomes rather than on risk factors
and model additional changes in risk factors and other
disease processes using more complex microsimulation
models.
Third, we chose to use the new ACC/AHA pooled cohort
equations to calculate 10-year atherosclerotic CVD risk
deﬁned as a composite end point of ﬁrst occurrence of
nonfatal myocardial infarction, death from coronary heart
disease, or fatal or nonfatal stroke. Other risk calculators—
the Framingham Heart Study Coronary Heart Disease calcu-
lator,38 the EURO-SCORE,39 and the Adult Treatment
Panel (ATP) III40 to name a few—are also used to calculate
risk scores for cardiovascular outcomes. While criticism over
use of the ACC/AHA risk equations exists,41–43 our model
focuses on a change in risk among strategies, so it would not
be affected by choice of risk algorithm.
Fourth, results may be sensitive to model inputs. Our
parameters are based on the best available published data,
namely, meta-analyses of controlled clinical trials. For exam-
ple, data on the effectiveness of yoga on risk factors were
obtained from a meta-analysis of RCTs of moderate quality
and generally small sample size.27 Other studies have,
however, corroborated the results and found improvements
of similar magnitude.25,26 Additionally, estimates for Mediter-
ranean diet were obtained from a meta-analysis of RCTs
involving overweight and obese patients, who in some cases
have access to additional advice and counseling29; the actual
beneﬁt may differ based on individual characteristics and
participation. As with all models, estimation is subject to the
data available and results should be interpreted recognizing
the limitations of the meta-analyses used.
Next, we recognize that patients have preferences for
certain approaches and doctors may have prescribing
preferences, including taking and prescribing medication,
respectively. We have presented a rank order of strategies
that do not include taking any pills or medication. As such,
nonadherence with lifestyle change and other health behav-
iors, including pill-taking, is of concern and may dilute
intervention effects. Our calculations are based on intention-
to-treat rates from the clinical trials, which incorporate
nonadherence. Personalized medicine may, in fact, aid
adherence to lifestyle changes.44 Nonetheless, real-world
adherence and associated risk improvement may differ from
what we have presented.
Lastly, we report risk reductions based on a single
intervention. It is possible that patients may try multiple
interventions simultaneously (eg, smoking cessation therapy
and walking) and that these interventions would reduce CVD
risk in a synergistic fashion. Furthermore, walking was chosen
as a comparator intervention in this study as it is considered
low-impact and widely accessible. More vigorous exercise
such as jogging may confer even greater cardiovascular and
ﬁtness beneﬁts and may change the rank order of strategies.
Clinical Implications and Policy Relevance
Studies on personalized medicine for preventive care have
found that some of the greatest gains in life expectancy come
from services targeting CVD.18,19,36 Accurate, personalized
recommendations regarding cardiovascular risk reduction can
Table 4. Percentage of Simulations That the Strategy Was
Ranked First (%) in the Secondary Analysis Assuming
Successful Cessation of Smoking, by Race-Speciﬁc Risk
Proﬁle
Highest-Ranked
Strategy
Risk Proﬁle
1 2 3 4 5 6
White
Group therapy for
smoking
N/A N/A 100.0 100.0 N/A 100.0
Mediterranean diet 0.4 0.4 0.0 0.0 0.2 0.0
Walking 4.9 4.9 0.0 0.0 4.9 0.0
Yoga 94.7 94.7 0.0 0.0 94.9 0.0
Black
Group therapy for
smoking
N/A N/A 100.0 100.0 N/A 100.0
Mediterranean diet 0.2 0.0 0.0 0.0 0.0 0.0
Walking 7.8 10.3 0.0 0.0 9.6 0.0
Yoga 92.0 89.7 0.0 0.0 90.4 0.0
N/A, not applicable.
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lead to better health and economic outcomes, reducing
healthcare and patient time costs, and increasing quality of
life and productivity. Use of risk estimators has been shown to
have signiﬁcant, modest effects on prescribing preventive
therapies and on risk factor levels.9,35,45,46
Based on this model and available data, yoga to reduce
CVD risk can be considered by physicians and patients as a
preventive-care strategy alongside smoking cessation, diet,
and exercise. The potential beneﬁt of yoga in lowering lipids,
BP, and body weight warrant further exploration of its health
effects and dose–response relationship in future clinical trials.
The information presented in this study has the potential to
help inform clinicians and patients on which activities could
be more effective at reducing long-term CVD risk based on
their personal risk and preferences for interventions. These
ﬁndings can be included in a decision aid used in the context
of shared decision-making between clinician and patient.
Additionally, the lifestyle management strategies analyzed in
this study require little to no equipment, no expensive
medication, and can be performed at home or at the
convenience of patients. Further research can examine
whether these low-cost strategies are cost-effective com-
pared to other CVD management strategies and demonstrate
whether tailored therapies do improve patient adherence and
health outcomes.
Conclusions
This study reports the comparative effectiveness of several
forms of lifestyle modiﬁcations, from the commonly advised
smoking cessation, diet, and exercise strategies to a more
contemporary form of exercise, yoga, on 10-year CVD risk.
For a current smoker, successfully quitting smoking is the
most effective lifestyle change. Smoking cessation is, how-
ever, difﬁcult to achieve and group therapy for stopping
smoking has only a small probability of success. From an
intention-to-treat perspective, if yoga is as effective as
reported in currently published meta-analyses, then yoga
could be considered among the strongest lifestyle interven-
tions for reducing CVD risk. With more individualized
estimates and recommendations, providers can better predict
CVD risk and manage prevention more effectively, particularly
among different ethnic groups who may be at higher risk of
CVD and can beneﬁt from early CVD risk discussion.47
Patients themselves can become more informed and involved
in their own health and lifestyle choices.
Tailored recommendations for managing CVD risk have the
potential to inform practice, improve care, and reduce
healthcare expenditures. Our analysis supports the ﬁndings
of several large-scale studies that CVD risk can be modiﬁed by
lifestyle changes. Additional research can take into account
adherence to management strategies as well as investigate
the effects of multiple interventions. As the interventions we
have included are relatively low cost, a priority for future
research is to analyze the effect of these management
strategies on quality of life, costs (ie, affordability), and cost-
effectiveness (ie, value for money).
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